HYAL1

Across TCGA pan-cancer cohorts, HYAL1 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of HYAL1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where HYAL1 RNA is repressed in tumor relative to normal tissue. In most cancer types HYAL1 is over-expressed in tumor, although a few such as KIRP and LUAD show the opposite, repressed pattern.

KIRP, LUAD, and KIRC are the cancer types where HYAL1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HYAL1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	III,IV	−2.899	<.001	11	view →
LUAD	Female	All	−2.717	<.001	11	view →
KIRC	Male	II,III,IV	−1.029	<.001	11	view →
THCA	All	III,IV	−0.755	<.001	10	view →
LUSC	Female	II,III,IV	−3.467	<.001	9	view →
HNSC	All	All	+0.819	<.001	9	view →
BLCA	All	IV	−1.735	<.001	8	view →
BRCA	All	II,III,IV	−1.503	<.001	6	view →
CHOL	Male	All	−2.119	<.001	2	view →
UCEC	All	All	−1.595	<.001	2	view →
PRAD	All	All	−0.319	<.001	2	view →
COAD	Female	IV	−0.805	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

HYAL1–KIRP

Open the KIRP breakdown →